###begin article-title 0
###xml 7 9 7 9 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 83 85 83 85 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
The P2Y13 Met-158-Thr Polymorphism, Which Is in Linkage Disequilibrium with the P2Y12 Locus, Is Not Associated with Acute Myocardial Infarction
###end article-title 0
###begin p 1
Conceived and designed the experiments: OM DE SA. Performed the experiments: LJ SA. Analyzed the data: OM LJ DE SA OB MR. Contributed reagents/materials/analysis tools: OM DE MR. Wrote the paper: OM LJ DE SA OB MR.
###end p 1
###begin title 2
Background and Aims
###end title 2
###begin p 3
###xml 53 55 53 55 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 86 88 86 88 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
The aims of this study were to investigate (1) if P2Y12 polymorphisms defining the P2Y12 H2 allele are associated with any other SNPs that may explain the previously reported association with increased ADP induced platelet activation and association with peripheral arterial disease and coronary artery disease and (2) if such variants are associated with acute myocardial infarction (AMI) or classical risk factors for AMI.
###end p 3
###begin title 4
Methods and Results
###end title 4
###begin p 5
###xml 7 9 7 9 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 94 96 94 96 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 141 142 141 142 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 177 179 177 179 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 186 188 186 188 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 319 321 319 321 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 449 451 449 451 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 773 775 773 775 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 919 921 919 921 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
The P2Y13 Met-158-Thr polymorphism was found to be in linkage disequilibrium (LD) with the P2Y12 H2 haplotype (all examined SNPs: D' = 1.0, r2 = 0.936-1.0), defining a novel P2Y12 H2/P2Y13 Thr-158 haplotype. Genotyping of an AMI case control population (n = 1244 cases, 2488 controls) revealed no association of the P2Y13 Thr-158 allele with AMI (OR = 0.96, 95% C.I. 0.82-1.12, P = 0.63). Also, no differences between the genotype frequencies of P2Y13 Met-158-Met and Met-158-Thr/Thr-158-Thr were seen in AMI case-control subpopulations (early onset AMI OR = 1.06, 95% C.I. 0.85-1.31, P = 0.62); family history of AMI (OR = 0.98, 95% C.I. 0.78-1.22, P = 0.83) nor in early onset AMIs with family history of AMI (OR = 1.0, 95% C.I. 0.74-1.36, P = 1.0). Genotyping of the P2Y13 Met-158-Thr polymorphism in a population based sample (n = 6055) revealed no association with cardiovascular risk factors. In addition, the P2Y13 Met-158-Thr polymorphism was genotyped in a diabetes case-control population, and associations were found neither with DM nor with any examined DM risk factors.
###end p 5
###begin title 6
Conclusion Genotyping
###end title 6
###begin p 7
###xml 7 9 7 9 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 62 64 62 64 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
The P2Y13 Met-158-Thr polymorphism is in tight LD with the P2Y12 locus but is not associated with AMI or classical cardiovascular risk factors.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 71 72 71 72 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 77 79 77 79 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 87 89 87 89 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 89 92 89 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Hollopeter1">[1]</xref>
###xml 93 96 93 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Communi1">[4]</xref>
###xml 115 116 115 116 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 124 126 124 126 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 183 186 183 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Murugappa1">[5]</xref>
###xml 225 227 225 227 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 358 361 358 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Wang1">[6]</xref>
###xml 388 390 388 390 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 412 414 412 414 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 516 519 516 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Hollopeter1">[1]</xref>
###xml 521 524 521 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Cattaneo1">[7]</xref>
###xml 526 529 526 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Remijn1">[8]</xref>
###xml 6 11 <span type="species:ncbi:9606">human</span>
Three human adenosine diphosphate (ADP) receptors have been cloned: P2Y1, P2Y12 and P2Y13[1]-[4]. On platelets, P2Y1 and P2Y12 mediate ADP-induced platelet activation and aggregation [5]. In red blood cells, activation of P2Y13 by the adenosine triphosphate (ATP) metabolite ADP activates a negative feedback loop that inhibits ATP release from erythrocytes [6]. Rare mutations in the P2Y12 gene that disrupt P2Y12 receptor function result in compromised ADP-induced platelet activation and increased bleeding times [1], [7], [8].
###end p 9
###begin p 10
###xml 34 36 34 36 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 167 169 167 169 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 279 282 279 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Bertrand1">[9]</xref>
###xml 443 447 443 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Wiviott1">[10]</xref>
The clinical importance of the P2Y12 receptor as a mediator of platelet activation has become evident in several large-scale clinical studies and inhibition of the P2Y12 receptor with clopidogrel is one of the cornerstones in treatment and prevention of acute coronary syndromes [9]. Even greater P2Y12 inhibition by prasugrel was recently shown to be even more effective in preventing ischemic events than the standard regimen of clopidogrel [10].
###end p 10
###begin p 11
###xml 60 62 60 62 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 94 96 94 96 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 110 114 110 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Fontana1">[11]</xref>
###xml 239 243 239 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Fontana1">[11]</xref>
###xml 244 248 244 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Ziegler1">[13]</xref>
###xml 270 275 270 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 359 363 359 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Cavallari1">[14]</xref>
###xml 577 581 577 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Cuisset1">[15]</xref>
###xml 582 586 582 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-vonBeckerath1">[17]</xref>
A group of single nucleotide polymorphisms (SNPs) in the P2Y12 gene, forming the so called P2Y12 H2 haplotype [11], have been associated with increased platelet responsiveness to ADP and increased risk of peripheral arterial disease (PAD) [11]-[13]. Recently, Cavallari et al showed an association of the P2Y12 H2 haplotype with coronary artery disease (CAD) [14]. It has also been proposed that this haplotype may account for variations in response to clopidogrel. However, several studies have failed to confirm any association between platelet function and the H2 haplotype [15]-[17].
###end p 11
###begin p 12
###xml 47 49 47 49 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 149 151 149 151 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 295 299 295 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Fontana1">[11]</xref>
###xml 376 378 376 378 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 416 418 416 418 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 467 469 467 469 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 512 514 512 514 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 550 552 550 552 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 611 613 611 613 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 682 684 682 684 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 801 804 801 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Communi1">[4]</xref>
###xml 806 809 806 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Wang1">[6]</xref>
###xml 912 914 912 914 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 939 941 939 941 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 1042 1044 1042 1044 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 1211 1215 1211 1215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Lee1">[18]</xref>
###xml 1217 1221 1217 1221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Criqui1">[19]</xref>
###xml 1250 1252 1250 1252 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 1293 1295 1293 1295 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 1390 1392 1390 1392 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 1441 1445 1441 1445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Cavallari1">[14]</xref>
###xml 1508 1512 1508 1512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-McCullough1">[20]</xref>
###xml 1791 1795 1791 1795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Amisten1">[21]</xref>
###xml 1797 1801 1797 1801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Manjer1">[22]</xref>
###xml 1888 1892 1888 1892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-OrhoMelander1">[23]</xref>
The group of polymorphisms that make up the P2Y12 H2 haplotype are all synonymous polymorphisms that do not change the amino acid sequence of the P2Y12 protein, and no mechanistic explanation to the reported increased platelet reactivity to ADP associated with this haplotype has been presented [11]. However, a non-synonymous polymorphism, Met-158-Thr, in the neighboring P2Y13 gene, located only 8 kb away from P2Y12, could be in linkage disequilibrium with the P2Y12 H2 haplotype. We hypothesized that the P2Y13 Met-158-Thr polymorphism of the P2Y13 receptor could account for the reported effects of the P2Y12 H2 haplotype since the receptors share the same ligand, ADP. The P2Y13 receptor has been found on red blood cells and inflammatory cells, both cell types known to interact with platelets [4], [6]. The first objective of this study was to examine possible linkage disequilibrium (LD) between the P2Y12 H2 haplotype and the P2Y13 Met-158-Thr polymorphism. After showing that this was the case, we aimed at investigating if the P2Y13 Met-158-Thr polymorphism is associated with acute myocardial infarction (AMI) or diabetes mellitus, two diseases strongly associated with peripheral arterial disease [18], [19]. Our hypothesis that the P2Y12 H2 haplotype and SNPs in LD with the P2Y12 H2 haplotype would be associated with AMI was strengthened further by a report linking the P2Y12 H2 haplotype with coronary artery disease (CAD) [14], since myocardial infarction is the major complication of CAD [20]. In order to do so, the Met-158-Thr polymorphism was genotyped in more than 10,000 individuals divided in three study populations: two sub-populations of the Malmo Diet and Cancer study (an AMI case-control population and a large population with cardiovascular risk factor data [21], [22]) and a diabetes mellitus case-control population with data on several DM risk factors [23].
###end p 12
###begin title 13
Materials and Methods
###end title 13
###begin title 14
Malmo diet and cancer population (MDC)
###end title 14
###begin p 15
###xml 59 62 <span type="species:ncbi:9606">men</span>
###xml 84 89 <span type="species:ncbi:9606">women</span>
The study population is made up of 28098 randomly selected men (born 1923-1945) and women (born 1923-1950) living in the Swedish city of Malmo (population 250 000). Overall participation rate in the study was 41%.
###end p 15
###begin p 16
###xml 346 350 346 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Amisten1">[21]</xref>
###xml 352 356 352 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Manjer1">[22]</xref>
A baseline examination was performed between 1991-1996, including assessment of dietary habits, a questionnaire on socio-economic, demographic and lifestyle factors, heredity, medication and previous and current diseases. Blood samples were taken and DNA, lymphocytes, granulocytes, erythrocytes and plasma/serum were stored in a biological bank [21], [22].
###end p 16
###begin title 17
AMI Case control population
###end title 17
###begin p 18
###xml 289 291 289 291 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th</sup>
###xml 298 300 298 300 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th</sup>
###xml 118 125 <span type="species:ncbi:9606">Patient</span>
###xml 384 391 <span type="species:ncbi:9606">Patient</span>
###xml 484 491 <span type="species:ncbi:9606">Patient</span>
On 31 December 2000 the study population was matched with the Swedish National Board of Health and Welfare's National Patient Registry and Cause of Death Registry. AMI cases (first AMI) were identified using the diagnosis criteria defined by the International Classification of Diseases, 9th and 10th and Revision, Clinical Modification (ICD 9 and 10); ICD 9 codes 410 in the Swedish Patient Registry or 410-414 in the Swedish Cause of death Registry; ICD 10 codes I21 in the Swedish Patient Registry and I21-I25 in the Swedish Cause of Death Registry.
###end p 18
###begin p 19
###xml 296 297 294 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 408 409 406 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 479 480 477 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 618 619 616 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 739 746 737 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001462-t001">table 1</xref>
###xml 796 797 794 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
Two gender- and age (+/-1 year) -matched AMI-free controls from the MDC population were assigned to each AMI case, resulting in a case-control material consisting of 1244 AMI cases and 2488 AMI-free controls. The myocardial infarction group was then further subdivided into early onset AMIs (EO, n = 622), age at first AMI event <62.8 years (median age of all first event AMI cases) and late onset AMIs (LO, n = 622, age at first AMI event >62.8 years). Family history AMIs (FH, n = 611) were defined as AMI cases where at least one blood related first degree family member had suffered an AMI, and non familial AMIs (n = 633) as cases without any first degree family history of AMI. 319 cases had both early onset and family history AMI (table 1). DNA was available from all cases and controls (n = 3732).
###end p 19
###begin title 20
###xml 126 128 126 128 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
Baseline characteristics of the AMI case control population and cardiovascular group population used for genotyping of the P2Y13 Thr-158 polymorphism.
###end title 20
###begin p 21
The 1244 AMI cases can be subdivided into three AMI subgroups: early onset AMI, defined as AMI occurring earlier than median age for all AMI cases, family history AMI, where at least one blood related family member also has suffered a myocardial infarction and early onset AMI with family history of AMI. Data of known cardiovascular risk factors was collected in the cardiovascular group only. * subgroups of all AMI cases.
###end p 21
###begin title 22
Cardiovascular group population
###end title 22
###begin p 23
Of the MDC, 6103 individuals were randomly selected into a "Cardiovascular cohort" (MDC-CV), a sample thus being representative of MDC, in whom cardiovascular risk factors were measured, including systolic blood pressure, smoking status and anthropometric data and, in the majority (n = 5540), fasting plasma analyses of glucose, lipids and C-reactive protein (CRP). DNA for genotyping was obtained from 6055 of the 6101 selected individuals.
###end p 23
###begin title 24
Diabetes mellitus case-control population
###end title 24
###begin p 25
###xml 73 77 73 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-OrhoMelander1">[23]</xref>
The diabetes mellitus case control material has been described elsewhere [23]. Briefly, all study subjects originate from the Botnia region in Western Finland and the Helsinki area and age- and gender matched controls were assigned to all type 2 diabetes cases. The case group is composed of 307 unrelated randomly selected individuals with type 2 diabetes (146 males and 161 females, mean age 61 (55-67) years, mean BMI 28.7 (26.0-31.7)). The control group consisted of 307 unrelated individuals with confirmed normal oral glucose tolerance and without a family history of diabetes (146 males and 161 females, mean age 60 (53-67) years, BMI 26.4 (24.1-29.2)).
###end p 25
###begin title 26
Extent of H2 haplotype linkage disequilibrium and genotyping of case-control and cardiovascular group populations
###end title 26
###begin p 27
###xml 350 352 350 352 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 391 393 391 393 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 452 456 452 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Fontana1">[11]</xref>
###xml 543 545 543 545 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 768 772 768 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Barrett1">[24]</xref>
###xml 21 26 <span type="species:ncbi:9606">Human</span>
Using HapMap and the Human Genome assembly build 36.2, SNPs in or within 1000 base pairs (bp) upstream of the known genes located in the 3q24-25 region (P2Y12 locus) were identified. By means of DNA sequencing using BigDye v. 3.1 (Applied Biosystems, CA, USA) in 20 individuals, selected SNPs were probed for linkage disequilibrium with the known P2Y12 H2 haplotype SNPs using one of the P2Y12 H2 SNPs, rs2046934, as a marker of the P2Y12 H2 haplotype [11]. Single nucleotide polymorphisms (SNPs) that displayed high degrees of LD with the P2Y12 H1/H2 haplotype SNPs were selected for genotyping in a randomly selected sub-population of the DM case-control population (n = 295) using TaqMan or Sequenom and a haplotype map was constructed using the Haploview software [24].
###end p 27
###begin p 28
###xml 394 401 394 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001462-t002">table 2</xref>
###xml 259 266 <span type="species:ncbi:9606">persons</span>
###xml 322 334 <span type="species:ncbi:9606">participants</span>
Genotyping of the AMI (n = 3732) and DM (n = 614) case control populations and the cardiovascular group population (n = 6055) was performed using Sequenom (Sequenom Inc., CA, USA) or TaqMan ABI 7900 according to the manufacturers' instructions. Two different persons who were unaware of the phenotypic status of the study participants read all genotypes. For genotyping primers and probes, see table 2.
###end p 28
###begin title 29
###xml 90 92 90 92 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 107 109 107 109 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
Primers and probes used for genotyping of high linkage disequilibrium polymorphisms in P2Y12 and one in P2Y13.
###end title 29
###begin p 30
Some SNPs were genotyped with both Sequenom and TaqMan in different populations. *Sequenom, # TaqMan.
###end p 30
###begin title 31
Statistical analysis
###end title 31
###begin p 32
In the AMI case control population, conditional logistic regression was used to calculate odds ratios and p values. The Cardiovascular group population was subjected to ANOVA and t-tests for continuous normally distributed variables, in case of non-normality Kruskal-Wallis test or Mann-Whitney test was used. Chi-2 test was used to test for significant differences in dichotomous variables. In the DM case control population, variables were log transformed for normal distribution. P-values were calculated using the GLM-ANCOVA using sex and age as covariates. Adjustment for multiple testing was not done. Statistical analyses were performed with SPSS.
###end p 32
###begin title 33
Power calculations
###end title 33
###begin title 34
For myocardial infarction
###end title 34
###begin p 35
###xml 147 149 147 149 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
Accepting a significance level of 0.05, 1244 AMI cases and 2488 controls have a power of 95% to detect a genotype relative risk of 1.20 for the P2Y13 Met-158-Thr polymorphism. Thus, it is unlikely that our result is a false negative finding.
###end p 35
###begin title 36
For diabetes
###end title 36
###begin p 37
###xml 150 152 150 152 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 369 371 369 371 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 489 491 489 491 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 634 638 634 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Skol1">[25]</xref>
Accepting a significance level of 0.05, 307 diabetes cases and 307 controls have a power of 35% to detect a genotype relative risk of 1.20 for the P2Y13 Met-158-Thr polymorphism. Accepting a significance level of 0.05, 532 diabetes cases and 5522 controls in the cardiovascular group population have a power of 79% to detect a genotype relative risk of 1.20 for the P2Y13 Met-158-Thr polymorphism. By analyzing both these two diabetes materials, it is unlikely that our result that the P2Y13 Met-158-Thr polymorphism is not associated with diabetes is a false negative finding. Powercalculations were performed using the program CaTS [25].
###end p 37
###begin title 38
Results
###end title 38
###begin title 39
###xml 13 15 13 15 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
Extent of P2Y12 H2 haplotype linkage disequilibrium
###end title 39
###begin p 40
###xml 60 62 60 62 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 167 169 167 169 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 275 277 275 277 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 308 309 308 309 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 323 331 323 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001462-g001">figure 1</xref>
###xml 333 337 333 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Fontana1">[11]</xref>
###xml 409 411 409 411 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 460 462 460 462 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 557 559 557 559 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 639 641 639 641 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 716 718 716 718 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 755 757 755 757 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 783 785 783 785 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 826 828 826 828 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 835 837 835 837 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 864 866 864 866 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 933 935 933 935 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 942 944 942 944 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
The pilot linkage disequilibrium analysis of SNPs in the P2Y12 locus revealed three SNPs (rs1466684, rs38211667, rs11922647) that showed signs of LD with the known P2Y12 H2 SNPs. Genotyping in a larger population (n = 295) confirmed complete LD of the three SNPs with the P2Y12 H2 haplotype SNPs (D' = 1.0, r2 = 0.936-1.0, figure 1) [11]. Two of the three SNPs were located in or in close proximity to the P2Y12 gene: rs38211667 in the non-coding region of P2Y12 exon 2 and rs11922647 within 1000 bp of transcription start of transcript variant 2 of the P2Y12 gene. The third SNP (rs1466684) was found to be a non-synonymous SNP of the P2Y13 gene, causing a Met-Thr amino acid substitution at position 158 of the P2Y13 receptor. The complete LD of the P2Y12 H2 haplotype with the P2Y13 Thr-158 variant thus defines a novel P2Y12 H2/P2Y13 Thr-158 haplotype. The P2Y13 Met-158-Thr polymorphism was selected as reference SNP for the P2Y12 H2/P2Y13 Thr-158 haplotype in subsequent genotyping.
###end p 40
###begin title 41
Linkage disequilibrium map of the P2Y12 H2/P2Y13 Thr-158 haplotype.
###end title 41
###begin p 42
###xml 85 86 85 86 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 132 133 132 133 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
All examined SNPs displayed a very high degree of linkage disequilibrium (D' = 1.0; r2 = 0.936-1.0 (see figure for each individual r2 value).
###end p 42
###begin title 43
###xml 21 23 21 23 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 30 32 30 32 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
Genotyping of the P2Y12 H2/P2Y13 Thr-158 haplotype in the AMI and DM case control populations
###end title 43
###begin p 44
###xml 145 152 145 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001462-t003">table 3</xref>
In the AMI case control population, containing 3273 individuals, 92.8% of those eligible for the case-control study were genotyped successfully (table 3), representing 1134 pairs in total (n = 1134 cases and one to two control subjects matching every case (n = 2139). Genotype frequencies were in accordance with Hardy-Weinberg Equilibrium.
###end p 44
###begin title 45
Genotyping of Met-158-Thr in AMI cases and corresponding controls.
###end title 45
###begin p 46
###xml 20 21 20 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 226 228 226 228 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
The AMI case group (n = 1244) contains the early onset (EO), late onset (LO), family history (FH) and no family history (NFH) as well as early onset with family history (EO+FH) subgroups. *Both heterozygous and homozygous P2RY13 Thr-158 carriers.
###end p 46
###begin p 47
###xml 25 27 25 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
No association of the P2Y13 Met-158-Thr polymorphism (Thr-158-Met and Thr-158-Thr vs. Met-158-Met) was found with AMI (OR = 0.96, 95% C.I. 0.82-1.12, P = 0.63). Also, no differences were seen in the AMI case subpopulations (EO OR = 1.06, 95% C.I. 0.85-1.31, P = 0.62; FH OR = 0.98, 95% C.I. 0.78-1.22, P = 0.83; EO+FH OR = 1.0, 95% C.I. 0.74-1.36, P = 1.0).
###end p 47
###begin p 48
###xml 256 263 256 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001462-t004">table 4</xref>
In the diabetes mellitus (DM) case control study 576 individuals (93.8%) were genotyped successfully. No associations of the P2Y13 polymorphism (Thr-158-Met and Thr-158-Thr vs. Met-158-Met) were found with diabetes mellitus or any examined DM risk factor (table 4).
###end p 48
###begin title 49
###xml 21 23 21 23 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 30 32 30 32 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
Genotyping of the P2Y12 H2/P2Y13 Thr-158 haplotype in a diabetes mellitus (DM) case control population (307 DM cases, 307 controls).
###end title 49
###begin p 50
###xml 245 247 245 247 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 254 256 254 256 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
Variables were log-transformed for normal distribution. P-values were calculated using the GLM-ANCOVA using sex and age as covariates. No associations were found with neither DM nor any known DM risk factor. *Both heterozygous and homozygous P2Y12 H2/P2Y13 Thr-158 carriers. section signGenotyping failed in 20 cases and 18 controls. #median with interquartile range (25th-75th percentile), [number of observations].
###end p 50
###begin title 51
###xml 17 19 17 19 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
Genotyping of P2Y13 Met-158-Thr in the cardiovascular group population
###end title 51
###begin p 52
###xml 132 134 132 134 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 430 437 430 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001462-t005">table 5</xref>
###xml 545 547 545 547 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
5846 individuals (96.5%) of 6055 in the cardiovascular group (CVG) were genotyped successfully. No association was found for the P2Y13 Met-158-Thr polymorphism (Thr-158-Met and Thr-158-Thr vs. Met-158-Met) regarding any of the examined cardiovascular risk factors, including systolic blood pressure, diastolic blood pressure, BMI, waist circ., diabetes, total cholesterol, triglycerides, HDL, LDL, CRP, smoking or alcohol intake (table 5). Furthermore, no stronger association with the above mentioned risk factors was seen in the homozygous P2Y13 Thr-158 group compared to the heterozygous Met-158-Thr carriers (data not shown).
###end p 52
###begin title 53
###xml 61 63 61 63 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 70 72 70 72 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
Association of known cardiovascular risk factors with the P2Y12 H2/P2Y13 Thr-158 genotype in the cardiovascular group (CVG).
###end title 53
###begin p 54
###xml 121 122 121 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 133 134 133 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 238 240 220 222 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
Gaussian distribution was observed for all above risk factors except CRP that showed a natural logarithmic distribution. n = 6055. * n = 5540. section sign = median, interquartile range. currencyThr = Both heterozygous and homozygous P2RY13 Thr-158 carriers.
###end p 54
###begin title 55
Discussion
###end title 55
###begin p 56
###xml 34 36 34 36 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 50 54 50 54 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Fontana1">[11]</xref>
###xml 152 154 152 154 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 175 177 175 177 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 184 186 184 186 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 254 256 254 256 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 264 266 264 266 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 355 357 355 357 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 410 412 410 412 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 574 576 574 576 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 625 629 625 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Fontana1">[11]</xref>
###xml 631 635 631 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Fontana2">[12]</xref>
###xml 637 641 637 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Cavallari1">[14]</xref>
###xml 721 723 721 723 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 1016 1020 1016 1020 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Lee1">[18]</xref>
###xml 1021 1025 1021 1025 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-McCullough1">[20]</xref>
###xml 1086 1093 1086 1093 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001462-t006">table 6</xref>
In this study we show that the P2Y12 H2 haplotype [11] is in complete linkage disequilibrium with the non-synonymous Met-158-Thr polymorphism in the P2Y13 gene, defining a P2Y12 H2/P2Y13 Thr-158 haplotype. Based on the observed LD between the studied P2Y12 and P2Y13 polymorphisms, we assume that all disease and risk factor associations made with the P2Y13 Met-158-Thr polymorphisms are also valid for the P2Y12 H1/H2 haplotypes. We hypothesized that this finding could provide a potential mechanistic explanation to the previously observed clinical associations of the P2Y12 H2 haplotype with CAD, PAD or platelet function [11], [12], [14], since the receptors share the same ligand. However, no associations of the P2Y13 Met-158-Thr polymorphism with AMI or DM were found in our large material. Indeed, no associations with any of the investigated cardiovascular or diabetes mellitus risk factors were observed. This was unexpected, since strong associations have been reported between CAD, PAD, AMI and diabetes [18]-[20]. All studies involving the P2Y12 H2 haplotype are listed in table 6.
###end p 56
###begin title 57
Published studies on the P2Y12 H2 haplotype and platelet ADP response and cardiovascular disease.
###end title 57
###begin p 58
###xml 210 214 210 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Coade1">[26]</xref>
###xml 327 330 327 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Wang1">[6]</xref>
###xml 332 336 332 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Bergfeld1">[27]</xref>
###xml 499 501 499 501 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 654 657 654 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Wang1">[6]</xref>
###xml 786 793 786 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 885 887 885 887 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 1001 1008 1001 1008 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1018 1027 1018 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in silico</italic>
###xml 1101 1105 1101 1105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Ramensky1">[28]</xref>
###xml 1128 1130 1128 1130 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 1212 1214 1212 1214 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
The concentration of extracellular nucleotides in the blood is tightly regulated by ectonucleotidases on leukocyte and endothelial cells to prevent excessive ADP accumulation and subsequent platelet activation [26]. Red blood cells contain millimolar amounts of ATP and are therefore a major source of nucleotides in the blood [6], [27]. This ATP pool could potentially be an important contributor to the regulation of platelet activation. Recently, it was shown that extracellular ADP activates P2Y13 expressed on red blood cells, resulting in a subsequent decreased release of nucleotides from the red blood cells in a classic negative feedback manner [6]. It is possible that this negative feedback loop might be important in the regulation of nucleotide-induced platelet activation in vivo. Thus, a non-synonymous polymorphism leading to a structurally and functionally altered P2Y13 could potentially alter the nucleotide concentrations in the blood stream, thereby affecting platelet activation in vivo. Indeed, in silico analysis using the polymorphism phenotyping prediction software PolyPhen [28] indicated that the P2Y13 Met-158-Thr amino acid substitution could possible affect the function of the P2Y13 receptor.
###end p 58
###begin p 59
###xml 16 21 16 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 38 40 38 40 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 284 286 284 286 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 444 446 444 446 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
In 2002 Fontana et al reported the P2Y12 H2 haplotype to be associated with a gain of function in terms of ADP induced platelet aggregation. The polymorphisms in the H2 haplotype are either located in intronic regions of the gene or were silent, i.e. causing no alterations of the P2Y12 receptor protein. The possibility remained that the polymorphisms could potentially be coupled to mRNA processing or translation events, thereby altering P2Y12 receptor protein expression. However, no such data has been presented.
###end p 59
###begin p 60
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 81 83 81 83 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 105 109 105 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Fontana2">[12]</xref>
###xml 269 273 269 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Leng1">[29]</xref>
###xml 462 466 462 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001462-Amisten1">[21]</xref>
###xml 201 209 <span type="species:ncbi:9606">patients</span>
In a subsequent study, Fontana et al also reported an association between the P2Y12 H2 haplotype and PAD [12]. PAD causes an increased atherosclerotic burden throughout the whole cardiovasculature and patients with PAD have a marked increase in coronary artery disease [29]. The progression of chronic atherosclerotic lesions is mainly driven by an inflammatory reaction, with recruitment of inflammatory cells and subsequent reactive changes in the vessel wall [21]. In acute thrombotic complications of atherosclerosis, such as myocardial infarction, platelets constitute the major role. A gain of function polymorphism leading to increased platelet reactivity would likely be more prominent when studied in a setting were platelet activation is a main pathogenic factor, such as AMI. However, to our surprise, genotyping in several thousand individuals revealed no association with AMI.
###end p 60
###begin p 61
###xml 208 210 208 210 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 217 219 217 219 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
The early onset or family history AMI case-control subpopulations are believed to contain a stronger genetic component of AMI. The lack of association also in these populations emphasizes further that the P2Y12 H2/P2Y13 Thr-158 haplotype is not associated with cardiovascular disease.
###end p 61
###begin p 62
###xml 33 35 33 35 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 397 399 397 399 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 406 408 406 408 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
It has been proposed that the P2Y12 H2 haplotype might be involved in the variation in response to clopidogrel treatment. However, subsequent studies have not been able to confirm that variations in response after a high loading dose of clopidogrel are associated with the haplotype. The failure to confirm this hypothesis agrees well with our study and supports the lack of association of the P2Y12 H2/P2Y13 Thr-158 haplotype with cardiovascular disease.
###end p 62
###begin p 63
###xml 36 38 36 38 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 95 97 95 97 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 132 134 132 134 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 141 143 141 143 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 381 383 381 383 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 391 393 391 393 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 477 478 477 478 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">.</bold>
In conclusion, we found that the P2Y13 Met-158-Thr polymorphism was in complete LD with the P2Y12 H2 haplotype, defining a novel P2Y12 H2/P2Y13 Thr-158 haplotype. Genotyping of more than 10 000 individuals in three separate study populations revealed no associations with AMI, DM or related risk factors. Therefore, it seems very unlikely that the examined polymorphisms of the P2Y12 and P2Y13 genes contribute to the pathogenesis of cardiovascular disease or diabetes mellitus.
###end p 63
###begin title 64
References
###end title 64
###begin article-title 65
Identification of the platelet ADP receptor targeted by antithrombotic drugs.
###end article-title 65
###begin article-title 66
###xml 44 49 <span type="species:ncbi:9606">human</span>
Cloning and chromosomal localization of the human P2Y1 purinoceptor.
###end article-title 66
###begin article-title 67
ADP is the cognate ligand for the orphan G protein-coupled receptor SP1999.
###end article-title 67
###begin article-title 68
###xml 26 31 <span type="species:ncbi:9606">human</span>
Identification of a novel human ADP receptor coupled to G(i).
###end article-title 68
###begin article-title 69
The role of ADP receptors in platelet function.
###end article-title 69
###begin article-title 70
###xml 82 87 <span type="species:ncbi:9606">human</span>
ADP acting on P2Y13 receptors is a negative feedback pathway for ATP release from human red blood cells.
###end article-title 70
###begin article-title 71
###xml 85 92 <span type="species:ncbi:9606">patient</span>
Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding.
###end article-title 71
###begin article-title 72
###xml 63 70 <span type="species:ncbi:9606">patient</span>
Novel molecular defect in the platelet ADP receptor P2Y12 of a patient with haemorrhagic diathesis.
###end article-title 72
###begin article-title 73
###xml 42 50 <span type="species:ncbi:9606">patients</span>
Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.
###end article-title 73
###begin article-title 74
###xml 32 40 <span type="species:ncbi:9606">Patients</span>
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes.
###end article-title 74
###begin article-title 75
Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects.
###end article-title 75
###begin article-title 76
P2Y12 H2 haplotype is associated with peripheral arterial disease: a case-control study.
###end article-title 76
###begin article-title 77
###xml 141 149 <span type="species:ncbi:9606">patients</span>
Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease.
###end article-title 77
###begin article-title 78
Gene sequence variations of the platelet P2Y12 receptor are associated with coronary artery disease.
###end article-title 78
###begin article-title 79
###xml 117 125 <span type="species:ncbi:9606">patients</span>
Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome.
###end article-title 79
###begin article-title 80
Association between platelet P2Y12 haplotype and risk of cardiovascular events in chronic coronary disease.
###end article-title 80
###begin article-title 81
P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose.
###end article-title 81
###begin article-title 82
Discovery and mapping of ten novel G protein-coupled receptor genes.
###end article-title 82
###begin article-title 83
###xml 39 47 <span type="species:ncbi:9606">patients</span>
Mortality over a period of 10 years in patients with peripheral arterial disease.
###end article-title 83
###begin article-title 84
Coronary artery disease.
###end article-title 84
###begin article-title 85
Increased risk of acute myocardial infarction and elevated levels of C-reactive protein in carriersof the Thr-87 variant of the ATP receptor P2Y11.
###end article-title 85
###begin article-title 86
###xml 85 97 <span type="species:ncbi:9606">participants</span>
###xml 106 118 <span type="species:ncbi:9606">participants</span>
The Malmo Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non-participants.
###end article-title 86
###begin article-title 87
Variants in the calpain-10 gene predispose to insulin resistance and elevated free fatty acid levels.
###end article-title 87
###begin article-title 88
Haploview: analysis and visualization of LD and haplotype maps.
###end article-title 88
###begin article-title 89
Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies.
###end article-title 89
###begin article-title 90
###xml 37 42 <span type="species:ncbi:9606">human</span>
Metabolism of adenine nucleotides in human blood.
###end article-title 90
###begin article-title 91
###xml 20 25 <span type="species:ncbi:9606">human</span>
Release of ATP from human erythrocytes in response to a brief period of hypoxia and hypercapnia.
###end article-title 91
###begin article-title 92
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human non-synonymous SNPs: server and survey.
###end article-title 92
###begin article-title 93
Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population.
###end article-title 93
###begin article-title 94
###xml 105 113 <span type="species:ncbi:9606">patients</span>
Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease.
###end article-title 94
###begin article-title 95
Dimorphism in the P2Y1 ADP receptor gene is associated with increased platelet activation response to ADP.
###end article-title 95
###begin p 96
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 96
###begin p 97
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: The study has been supported by the Swedish Scientific Research Council, the Swedish Heart and Lung Foundation Lund University Hospital funds and the Vascular Wall program (Lund Medical faculty).
###end p 97

